Radiotherapy had a very active week on LinkedIn from June 1 to June 7, with posts that captured the field from several different angles: new clinical evidence, adaptive treatment workflows, digital innovation, supportive care, multidisciplinary collaboration, and the personal stories behind research.
This week’s selection includes important updates on SABR for oligometastatic melanoma in patients receiving immunotherapy, including strong local control outcomes and a thoughtful reflection on how melanoma, immunotherapy, and stereotactic ablative radiotherapy are increasingly coming together in modern practice.
There was also a strong focus on the evolving evidence around combining radiotherapy with immunotherapy, including tools that help clinicians quickly access randomized data by tumor type, endpoint, and subgroup. As RT and systemic therapy become more closely integrated, these kinds of living evidence platforms are becoming increasingly useful for daily clinical decision-making.
Several posts highlighted the rapid progress in adaptive and image-guided radiotherapy, from MR-guided adaptive workflows and MR-enhanced treatment approaches to new ideas around digital twins in hadrontherapy. These updates show how radiation oncology continues to move toward more personalized, biologically informed, and technically precise care.
The week also reminded us that oncology is not only about technology and trials. Posts on therapy dogs, supportive care, patient experience, and the value of human connection brought an important balance to the conversation. They showed that improving cancer care also means reducing anxiety, supporting patients emotionally, and making treatment spaces feel more humane.
From melanoma SABR and immunotherapy to lung oncology collaborations, MR-adaptive radiotherapy, hadrontherapy digital twins, urothelial cancer biomarkers, and supportive care, these are the radiation oncology posts from June 1–7 that people should not miss.
Damir Vučinić – Radiation Oncologist at Radiochirurgia Zagreb
I’m proud to share that our work, “Stereotactic Body Radiotherapy for Oligometastatic Disease in Melanoma Patients Receiving Immunotherapy: A Single-Center Retrospective Analysis,” has been published in Cancers MDPI journal ranked Q1 in Oncology by CiteScore, IF 4.4.
Excellent local control
95.9% at 12 months and 89.7% at 24/36 months.
Encouraging survival
Median overall survival was 47 months; median PFS was not reached
Treatment timing matters
SABR before or during immunotherapy was associated with a numerical trend toward longer progression-free survival.
Personally, I consider this one of the most important papers of my career so far. Not only because of the results, but because it brings together three fields that have shaped my professional path: melanoma, which I have been involved with since medical school; immunotherapy, the focus of my PhD research; and SABR, which is now at the center of my daily clinical work. Combining stereotactic ablative radiotherapy with immunotherapy is not only a technical challenge. It requires a deep understanding of radiobiology, the immune response, treatment timing, and how local therapy can be integrated into a broader systemic antitumor strategy. I’m especially proud of the outstanding work of the entire team at Radiochirurgia Zagreb, Cleveland Clinic Connected — not only on this publication, but also in the everyday care of our patients.
I truly believe this is the path we should continue to follow: precise, multidisciplinary, biologically informed, and always focused on offering more to our patients.
#melanoma #immunotherapy #SABR #SBRT #RadiationOncology
Axel Licha – Radiation Oncology Resident at Institut Godinot
Today, the best supportive care intervention in our hospital had four legs.
At the Institut Godinot, between treatments, scans, consultations, and long hours of waiting, a few minutes with a therapy dog can sometimes bring back a smile that illness had taken away.
Animal-assisted interventions are increasingly recognized as valuable components of supportive and integrative care, helping to reduce anxiety, emotional distress, and feelings of isolation throughout the cancer journey.
They remind us of a simple but essential truth:
Caring for a patient with cancer also means caring for the human being living through it. Sometimes, the most modern medicine is not the most technological.#Oncology #RadiationOncology hashtag#CancerCare #SupportiveCare #IntegrativeMedicine #PatientExperience #QualityOfLife #CancerTreatment #Healthcare #HumanizingHealthcare #InstitutJeanGodinot
Andrea D’Aviero – Associate Professor of Radiation Oncology at AIRO – Associazione Italiana Radioterapia e Oncologia clinica
Great discussions, new ideas, and exciting projects at the first 2026 AIRO – Associazione Italiana di Radioterapia ed Oncologia Clinica Lung Study Group meeting in Rome.
Together, we’ve got game.
#AIRO #ThoracicOncology #Research #Collaboration
Peter van Rossum – Radiation oncologist | Epidemiologist at Amsterdam UMC
Looking for the latest hashtag#randomized hashtag#evidence on combining hashtag#radiotherapy and hashtag#immunotherapy in your specific field of interest?
Try our LIVING hashtag#MetaAnalysis platform at the Immunorad website: https://lnkd.in/e3f9E-j7
Within seconds, you can:
Select the hashtag#tumor type you’re interested in
Choose the hashtag#survival endpoint (OS, PFS, EFS, and more)
Even dive into relevant hashtag#subgroups…and instantly access the most hashtag#uptodate randomized evidence on RT + immune checkpoint inhibitors.
An essential reference for every practicing hashtag#radiation hashtag#oncologist.
Read the accompanying publication in the European Journal of Cancer
Sandro V Porceddu – Director, Department of Radiation Oncology at Peter MacCallum Cancer Centre
Beat the Deadline! Early Registration for IFHNOS World Congress 2026 closes on 9 June 2026. Register before 11:59pm AEST to secure the discount.
The Congress will host over 40 countries, hold 224 invited presentations from 211 invited speakers and 139 proferred oral presentations and 169 poster presentations. This will be a truly global head and neck cancer event hosted in Brisbane.
Filippo Alongi – Professor and Chairman of Advanced Radiation Oncology at Università degli Studi di Brescia
IARTIST meeting in Istanbul: session on oligometastatic disease and metastasis direct therapy. June 13th, 2026.
Waiting for your vote!
Alessandro Mencarelli – Pioneer of MRI in Radiotherapy at Universitätsspital Zürich
Did you know that MR Online Adaptive RT is possible also without an MR-Linac?
Check out our new work on;
<Integrating a Stand-alone MR-Simulator and C-Arm Linear Accelerator for Improved Treatment Efficiency of MR-Enhanced Adaptive Radiation Therapy>Is impressive the efficiency of this workflow being able to treat online adaptive plans without interrupting the schedule of a Linear Accelerator.
We have something to say also about metal artifacts on low field MRI
Felipe Couñago – Medical Director at GenesisCare Spain | Radiation Oncologist
What happens after the symposium may be just as important as what happens during it.
At SEOR 2026, we had the privilege of bringing together an extraordinary group of experts to discuss the future of MR-guided adaptive radiotherapy.
We learned from internationally recognized leaders such as Filippo Alongi , Drew Moghanaki, MD, MPH, FASTRO , Michael Chuong, MD, FACRO whose work continues to shape the future of radiation oncology worldwide.
The science was outstanding.
The conversations were even better.
And somewhere between discussing adaptive workflows, pancreatic SBRT, real-time tumour visualization, and the future of MRI-guided treatments, we apparently found time to:
inspect giant mushrooms, pose for questionable selfies, enjoy great dinners, share plenty of laughs, explore Alicante,and prove that radiation oncologists can occasionally have fun too!
These moments are a wonderful reminder that innovation is driven not only by technology and evidence, but also by friendship, collaboration, and a shared passion for improving patient care .
Thank you to everyone who made these days so memorable.
The lectures may end, but the conversations continue.
Juliette Thariat – Professor in Radiation Oncology at Centre Baclesse/ Institut Universitaire de France
I am delighted to announce that our aRTwin (artificial Intelligence-based RadioTherapy digital Twins) project has been awarded Normandy–Europe funding (Supporting Digital Transformation) to launch key research activities supporting accelerated transition toward truly predictive and personalized medicine integrating multi-particle hadrontherapy in Normandy.
Hadrontherapy (protons, helium ions, and carbon ions) represents one of the most promising advances in state-of-the-art radiation oncology. Yet a fundamental question remains: How can we identify the optimal radiation treatment for the individual patient sitting in front of us?
With aRTwin, we aim to build patient-specific digital twins by combining:
physical models describing particle transport and dose deposition;
physico-chemical and biological mechanisms, from oxidative stress to DNA damage;
radiobiological models describing tumor response and normal tissue toxicities;
real-world patient data (imaging, dosimetry, clinical outcomes, observed toxicities) to continuously calibrate and improve the models.
Our goal is to reconcile the equations that describe the mechanisms of living systems with real-world clinical data to create a true simulation platform.
We will virtually compare multiple treatment scenarios; photons, protons, helium ions, or carbon ions; before treatment even begins, allowing us to identify for each patient the strategy offering the best balance between:
Tumor control
Quality of life
Toxicity reduction
This project builds on the exceptional ecosystem developed in Normandy around the Centre François Baclesse, CYCLHAD, JAKALA, Caen University Hospital, GANIL, CYCERON/ISTCT, LPC Caen/IN2P3/CNRS, the University of Caen Normandy, and many other outstanding partners.
#aRTwin #DigitalTwin #ArtificialIntelligence #Radiotherapy #HadronTherapy #CarbonIons #ProtonTherapy #PrecisionMedicine #Oncology #MedicalAI #Baclesse #CYCLHAD #Normandy #PTCOG2026
Konrad Stawiski – Radiation Oncologist at Copernicus Memorial Hospital in Lodz
I’m pleased to share our new open-access article in Molecular Oncology:
“Tumor B-cell infiltration in platinum-treated advanced muscle-invasive urothelial carcinoma”
In this international study, we analyzed pretreatment tumor transcriptomes from 189 patients with advanced urothelial carcinoma treated with platinum-based chemotherapy across three independent cohorts.
The key finding: the immune tumor microenvironment matters. Higher lymphocyte infiltration was associated with longer overall survival, with the strongest signal observed for B cells—especially memory B cells. This favorable immune context was most evident in patients treated with cisplatin and in tumors showing a pro-inflammatory, B-cell-rich/TLS-related ecosystem.
These results support further development of B-cell- and tertiary lymphoid structure–focused biomarkers in urothelial cancer and highlight the value of integrating transcriptomics, bioinformatics, and tumor microenvironment analysis in precision oncology.
Read the article
Read 10 Must-Read Posts of week May 25- May 31